Back to today’s briefing

Story perspectives

Promising Vaccine ELI-002 2P Shows 84% Immune Response

8/14/2025

42 3

Summary

Story summary

A groundbreaking experimental vaccine, ELI-002 2P, is making waves in the fight against pancreatic and colorectal cancers. In a Phase I trial involving 25 post-surgery patients, it achieved an impressive 84% immune response and a median relapse-free survival of 15.3 months. Exciting future trials are set to validate its effectiveness and expand its potential uses.

1 of 1

Story summary

A groundbreaking experimental vaccine, ELI-002 2P, is making waves in the fight against pancreatic and colorectal cancers. In a Phase I trial involving 25 post-surgery patients, it achieved an impressive 84% immune response and a median relapse-free survival of 15.3 months. Exciting future trials are set to validate its effectiveness and expand its potential uses.